Results 261 to 270 of about 133,537 (299)

Correction to "Oxaliplatin-Induced Hypersensitivity Reactions Resulting in Respiratory and Cardiac Arrest: A Rare Case". [PDF]

Clin Case Rep
europepmc   +1 more source

Remarkable Responses to Chemoimmunotherapy in Ultra-Rare Urachal Cancer: A Case Series and Reverse Translational Research. [PDF]

MedComm (2020)
Kotani H, Sato S, Shigehara K, Saito D, Sakaguchi H, Nishiyama A, Matsumoto I, Mizokami A, Yano S, Taniguchi H.   +9 more
europepmc   +1 more source

Correction to "Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients". [PDF]

J Oncol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Journal of Clinical Oncology, 2023
Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic ...
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, R. Wong, S. Koski, M. Lichinitser, T-S. Yang, F. Rivera, F. Couture, F. Sirzén, J. Cassidy   +12 more
semanticscholar   +1 more source

Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised c

The Lancet Oncology, 2021
BACKGROUND The optimal perioperative chemotherapeutic regimen for locally advanced gastric cancer remains undefined. We evaluated the efficacy and safety of perioperative and postoperative S-1 and oxaliplatin (SOX) compared with postoperative ...
Xiaotian Zhang, Han Liang, Ziyu Li, Yingwei Xue, Yanong Wang, Zhiwei Zhou, Jiren Yu, Z. Bu, Lin Chen, Yi-an Du, Xinbao Wang, A. Wu, Guoli Li, X. Su, G. Xiao, M. Cui, Dan Wu, Li Chen, Xiaojiang Wu, Yanbing Zhou, Lianhai Zhang, C. Dang, Yulong He, Zhongtao Zhang, Yihong Sun, Yong Li, Huan-qiu Chen, Y. Bai, C. Qi, P. Yu, G. Zhu, J. Suo, B. Jia, Leping Li, Chang-ming Huang, Fei Li, Y. Ye, Huimian Xu, Xin Yu Wang, Yannan Yuan, J. E, X. Ying, C. Yao, L. Shen, J. Ji   +44 more
semanticscholar   +1 more source

Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death.

ACS Nano, 2022
The nanocatalytic activity of nanozymes provides a vision for tumor treatment. However, the glutathione (GSH)-related antioxidant defense system (ADS) formed on the basis of excessive GSH in the tumor microenvironment limits its catalytic activity. Here,
Feng Wu, Yaqian Du, Jiani Yang, Boyang Shao, Zhensheng Mi, Yuanfei Yao, Ying Cui, Fei He, Yanqiao Zhang, Piaoping Yang   +9 more
semanticscholar   +1 more source

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Journal of Clinical Oncology, 2019
PURPOSE No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether gemcitabine and oxaliplatin chemotherapy (GEMOX) would increase relapse-free survival (RFS) while
J. Edeline, M. Benabdelghani, A. Bertaut, J. Watelet, P. Hammel, J. Joly, K. Boudjema, L. Fartoux, K. Bouhier‐Leporrier, J. Jouve, R. Faroux, V. Guérin-Meyer, J. Kurtz, E. Assenat, J. Seitz, I. Baumgaertner, D. Tougeron, C. de la Fouchardière, C. Lombard-Bohas, E. Boucher, T. Stanbury, C. Louvet, D. Malka, J. Phelip   +23 more
semanticscholar   +1 more source

LSD1‐Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1‐Induced p62 Transcription in HCC

Hepatology, 2021
Oxaliplatin (OXA) is one of the most common chemotherapeutics in advanced hepatocellular carcinoma (HCC), the resistance of which poses a big challenge. Long noncoding RNAs (lncRNAs) play vital roles in chemoresistance.
Luyuan Ma, A. Xu, L. Kang, Rui Cong, Zhong-yi Fan, Xiang Zhu, Nan Huo, Wenpeng Liu, C. Xue, Q. Ji, Wenchao Li, Zhong Chu, Xiaofeng Kang, Ya-dong Wang, Zhijia Sun, Yuchen Han, Hanxiao Liu, Xiang Gao, Juqiang Han, Hua You, Caiyan Zhao, Xiaojie Xu   +21 more
semanticscholar   +1 more source